Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity
Open Access
- 25 April 2022
- journal article
- research article
- Published by Springer Nature in BMC Biology
- Vol. 20 (1) , 1-16
Abstract
Background: The CRISPR-Cas12a (formerly Cpf1) system is a versatile gene-editing tool with properties distinct from the broadly used Cas9 system. Features such as recognition of T-rich protospacer-adjacent motif (PAM) and generation of sticky breaks, as well as amenability for multiplex editing in a single crRNA and lower off-target nuclease activity, broaden the targeting scope of available tools and enable more accurate genome editing. However, the widespread use of the nuclease for gene editing, especially in clinical applications, is hindered by insufficient activity and specificity despite previous efforts to improve the system. Currently reported Cas12a variants achieve high activity with a compromise of specificity. Here, we used structure-guided protein engineering to improve both editing efficiency and targeting accuracy of Acidaminococcus sp. Cas12a (AsCas12a) and Lachnospiraceae bacterium Cas12a (LbCas12a). Results: We created new AsCas12a variant termed “AsCas12a-Plus” with increased activity (1.5~2.0-fold improvement) and specificity (reducing off-targets from 29 to 23 and specificity index increased from 92% to 94% with 33 sgRNAs), and this property was retained in multiplex editing and transcriptional activation. When used to disrupt the oncogenic BRAFV600E mutant, AsCas12a-Plus showed less off-target activity while maintaining comparable editing efficiency and BRAFV600E cancer cell killing. By introducing the corresponding substitutions into LbCas12a, we also generated LbCas12a-Plus (activity improved ~1.1-fold and off-targets decreased from 20 to 12 while specificity index increased from 78% to 89% with 15 sgRNAs), suggesting this strategy may be generally applicable across Cas12a orthologs. We compared Cas12a-Plus, other variants described in this study, and the reported enCas12a-HF, enCas12a, and Cas12a-ultra, and found that Cas12a-Plus outperformed other variants with a good balance for enhanced activity and improved specificity. Conclusions: Our discoveries provide alternative AsCas12a and LbCas12a variants with high specificity and activity, which expand the gene-editing toolbox and can be more suitable for clinical applications.Keywords
Funding Information
- The National Key R&D Program of China (2017YFA0105001)
- The National Natural Science Foundation of China (82070002, 81872511)
- The National Natural Science Foundation of China (82072329)
- the fellowship of China Postdoctoral Science Foundation (2021M701615, 2021M691473, 2021M701634)
This publication has 78 references indexed in Scilit:
- The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNANature, 2016
- High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effectsNature, 2016
- Rationally engineered Cas9 nucleases with improved specificityScience, 2016
- Orthogonal gene knockout and activation with a catalytically active Cas9 nucleaseNature Biotechnology, 2015
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas SystemCell, 2015
- GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleasesNature Biotechnology, 2014
- Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondNature Reviews Cancer, 2014
- Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteinsGenome Research, 2014
- Crystal Structure of Cas9 in Complex with Guide RNA and Target DNACell, 2014
- Improving CRISPR-Cas nuclease specificity using truncated guide RNAsNature Biotechnology, 2014